Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ºÚÁÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Despite recent advances in breast cancer therapeutics, mortality of highly metastatic triple negative breast cancer (TNBC)
subtype remains high; due to their lack of hormone receptors expression for targeted therapy. Therefore, there is a pressing
need to identify new prognostic markers and therapeutic targets for this group of breast cancers. Aberrant activation of Wnt/�²-
catenin signaling has been associated with breast cancers; where 40% of total breast cancers have elevated �²-catenin levels and/
or Wnt activity. Herein, we identify DEAD-box RNA helicase DP103 as a novel driver of Wnt/�²-catenin pathway in TNBC. The
link between DP103 and Wnt/beta-catenin signaling was further validated using in vivo Zebrafish models, where disruption in
DDX20 gene splicing mechanisms resulted in severe early embryonic developmental defects which phenocopies loss of Wnt/
beta-catenin signaling during gastrulation. Interestingly, we also show DP103 drives breast cancer stem cell (CSC) formation,
a process regulated by the Wnt/beta-catenin pathway. Depletion of DP103 led to a marked reduction in the percentage of
CSC-enriched mammospheres with reduced tumor-initiating ability. Mechanistically, we show DP103�s role in driving Wnt/
beta-catenin pathway is independent of casein kinase I activity but highly dependent on GSK3�² activity. More interestingly,
from molecular docking data, we found DP103 protein has to be phosphorylated at threonine residue 552, when it interacts
with GSK3�². Surprisingly, induction of Wnt/�²-catenin signaling also significantly increased DP103 expression, indicating a
possible positive feedback loop. Collectively, our data suggest a novel regulatory role of DP103 in the Wnt/�²-catenin signaling
pathway in parental and CSC derived TNBC.